Z
Zynerba Pharmaceuticals Inc
F:6ZY
Zynerba Pharmaceuticals Inc
F:6ZY
Price:
1.26
EUR
2.44%
Market Cap:
€67.6m
Balance Sheet
Balance Sheet Decomposition
Zynerba Pharmaceuticals Inc
Zynerba Pharmaceuticals Inc
Balance Sheet Decomposition is not available for
Zynerba Pharmaceuticals Inc
Zynerba Pharmaceuticals Inc
Balance Sheet
Zynerba Pharmaceuticals Inc
Zynerba Pharmaceuticals Inc
Currency: USD
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
0
|
9
|
42
|
31
|
63
|
60
|
70
|
59
|
68
|
51
|
|
| Cash Equivalents |
0
|
9
|
42
|
31
|
63
|
60
|
70
|
59
|
68
|
51
|
|
| Total Receivables |
0
|
0
|
0
|
4
|
4
|
3
|
15
|
9
|
10
|
1
|
|
| Other Current Assets |
1
|
2
|
2
|
2
|
2
|
4
|
2
|
5
|
3
|
3
|
|
| Total Current Assets |
1
|
12
|
43
|
36
|
68
|
67
|
87
|
73
|
80
|
55
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
|
| Accumulated Depreciation |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
|
| Other Long-Term Assets |
1
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
2
N/A
|
12
+525%
|
44
+276%
|
37
-16%
|
69
+89%
|
67
-2%
|
88
+30%
|
74
-16%
|
81
+10%
|
56
-32%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
0
|
0
|
1
|
2
|
3
|
4
|
5
|
3
|
2
|
2
|
|
| Accrued Liabilities |
0
|
0
|
2
|
4
|
4
|
5
|
7
|
11
|
8
|
7
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
1
|
3
|
1
|
1
|
0
|
1
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
2
|
3
|
4
|
7
|
7
|
10
|
12
|
14
|
10
|
9
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
1
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
3
N/A
|
3
+3%
|
4
+25%
|
7
+77%
|
8
+16%
|
10
+20%
|
12
+25%
|
14
+14%
|
10
-26%
|
9
-9%
|
|
| Equity | |||||||||||
| Common Stock |
3
|
17
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
4
|
10
|
23
|
46
|
78
|
118
|
151
|
202
|
239
|
275
|
|
| Additional Paid In Capital |
0
|
2
|
62
|
76
|
139
|
175
|
226
|
262
|
310
|
321
|
|
| Total Equity |
1
N/A
|
8
N/A
|
40
+369%
|
30
-25%
|
61
+106%
|
58
-5%
|
76
+31%
|
60
-20%
|
71
+18%
|
46
-35%
|
|
| Total Liabilities & Equity |
2
N/A
|
12
+525%
|
44
+276%
|
37
-16%
|
69
+89%
|
67
-2%
|
88
+30%
|
74
-16%
|
81
+10%
|
56
-32%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
9
|
9
|
9
|
10
|
14
|
18
|
23
|
30
|
41
|
48
|
|
Switch to:
Switch to:
See Also
Discover More
